PACBHIGH SIGNALFINANCIAL10-K

PACB completed a $50 million asset sale to Illumina while experiencing a catastrophic decline in stockholders' equity from $506.6M to $5.3M.

The company has divested its short-read DNA sequencing technology to Illumina for $50 million while pivoting to focus solely on long-read sequencing technology. The near-complete erosion of stockholders' equity signals severe financial distress that raises questions about the company's ability to continue operations without additional capital infusion or restructuring.

Comparing 2026-02-25 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

PACB shows a company in severe financial distress with stockholders' equity collapsing by 98.9% to just $5.3 million while net losses expanded substantially to $546.4 million. Despite some positive signs including 22.8% gross profit growth and improved operating cash flow burn, the company reduced R&D spending by 27.9% and cut capital expenditures by over half, suggesting cost-cutting measures amid the financial crisis. The $50 million asset sale to Illumina provides some near-term liquidity but appears insufficient given the magnitude of losses and equity deterioration.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-98.9%
$506.6M→$5.3M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Net Income
P&L
-76.3%
-$309.9M→-$546.4M

Net income declined 76.3% — review whether driven by operations, interest costs, or non-recurring items.

Capital Expenditure
Cash Flow
-56.1%
$6.2M→$2.7M

Capex reduced 56.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+46%
-$206.1M→-$111.2M

Operating cash flow surged 46% — exceptional cash generation, highest quality earnings signal.

Total Assets
Balance Sheet
-37.8%
$1.3B→$784.1M

Total assets contracted 37.8% — asset sales, write-downs, or balance sheet optimization underway.

Accounts Receivable
Balance Sheet
+28.8%
$27.5M→$35.4M

Receivables grew 28.8% — monitor days sales outstanding for collection efficiency.

R&D Expense
P&L
-27.9%
$134.9M→$97.3M

R&D spending cut 27.9% — could signal cost discipline or concerning reduction in innovation investment.

Current Assets
Balance Sheet
-24.3%
$495.7M→$375.1M

Current assets declined 24.3% — monitor working capital adequacy and short-term liquidity.

Gross Profit
P&L
+22.8%
$37.3M→$45.8M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

SG&A Expense
P&L
-19.2%
$175.0M→$141.5M

SG&A reduced 19.2% — improved cost efficiency or headcount reduction improving operating margins.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-03-17
ADDED
Forward-looking statements can be identified by words such as: anticipates, believes, could, estimates, expects, intends, may, plans, potential, predicts, projects, seeks, should, target, will, would, or similar expressions and the negatives of those terms.
Our products and technology, which include our HiFi long-read sequencing technology, address a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.
Recent Developments On January 30, 2026, we completed the disposition of assets to Illumina Cambridge Limited (the Buyer ) in accordance with the terms of an Asset Purchase Agreement, dated January 30, 2026 (the Asset Purchase Agreement ), by and among us, Buyer, and Illumina, Inc.
("Illumina"), solely for purposes of Section 8.16 of the Asset Purchase Agreement, pursuant to which, among other matters, Buyer acquired certain intellectual property and other assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies (the Asset Sale ).
As consideration for the Asset Sale, Buyer paid us $50.0 million in cash and assumed certain liabilities (the Purchase Price ).
+7 more — sign up free →
REMOVED
Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB TM ) short-read sequencing technology.
Our products address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.
Lo ng-read sequencing was recognized by the journal Nature Methods as its method of the year for 2022 for its contributions to biological understanding and future potential.
Long-read sequencing has been applied to produce telomere-to-telomere genomes of humans, pangenome references, and has been recognized for its ability to provide more complete views of human variation .
Recent Developments In 2024, we launched Vega TM , a revolutionary new benchtop sequencer designed to make accurate long-read sequencing accessible to more laboratories than ever before.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →